Benitec Biopharma

Benitec Biopharma Gross Margin

The Gross Margin of Benitec Biopharma (BNTC) as of Oct 19, 2026 is 100.00 %. In the previous year, Gross Margin was 85.71 % — a change of 16.67% (higher).

Gross Margin

100.00 %

YoY

16.67%

Last updated:

Gross Margin of Benitec Biopharma is 2023 100.00 % . Gross Margin of Benitec Biopharma was 2022 85.71 % . It decreases by 16.67% higher compared to the previous year.

Benitec Biopharma's gross margin stands at 100.0%, up from 96.3% several years earlier.

The Benitec Biopharma Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2016
96.61 USD
Jan 1, 2017
97.49 USD
Jan 1, 2018
90.22 USD
Jan 1, 2019
96.29 USD
Jan 1, 2020
290.00 USD
Jan 1, 2021
-100.00 USD
Jan 1, 2022
85.71 USD
Jan 1, 2023
100.00 USD
The Benitec Biopharma Gross Margin history
YEARGross MarginYoY
100.00 %+16.67%
85.71 %-185.71%
-100.00 %-134.48%
290.00 %+201.16%
96.29 %+6.73%
90.22 %-7.45%
97.49 %+0.91%
96.61 %-2.00%
98.59 %+15.02%
85.71 %+8,646.36%
0.98 %+27.40%
0.77 %-15.63%
0.91 %+21.57%
0.75 %+1.25%
0.74 %-7.41%
0.80 %+4.83%
0.76 %-12.56%
0.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Benitec Biopharma Stock analysis

What does Benitec Biopharma do? Benitec Biopharma Inc, based in Melbourne, Australia, operates in the Health Care sector, specializing in biotechnology. The company focuses on developing therapeutic agents using RNA interference and gene therapy to treat genetic disorders. It employs 19 people and is listed on the market since 2012. Benitec is advancing a pipeline including BB-301 for Oculopharyngeal Muscular Dystrophy and BB-103 for Hepatitis B, utilizing its ddRNAi technology for sustained gene silencing from a single treatment. Benitec Biopharma Inc is a biotechnology company headquartered in Melbourne, Victoria, dedicated to developing innovative genetic medicines. It leverages its ddRNAi platform to create therapies that provide long-term silencing of disease-causing genes with a single administration, targeting chronic and life-threatening conditions such as orphan diseases and infectious diseases. Benitec Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Benitec Biopharma stock

Gross Margin of Benitec Biopharma is 100.00 % in 2023.

Gross Margin of Benitec Biopharma changed from 85.71 % to 100.00 %, representing a 16.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Benitec Biopharma since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Benitec Biopharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Benitec Biopharma

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Benitec Biopharma